1. NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS

3. What Does Registry Data Tell Us?

4. Which Questions Should I Ask When Looking at Registry Data?

5. CV, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for NVAF

6. CV, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for NVAF- (cont)

7. 2016 ESC Guidelines: Stroke Prevention in AF

8. NOAC Use In Patients With Valvular Abnormalities

9. RCTs and Real-World Data: How Do They Differ?

10. Danish Registry: A Nationwide Cohort

11. Societal Registries: EORP-AF

12. GLORIA™-AF: Prospective Study With Dabigatran Use -- 2-Year Follow Up

13. GLORIA™-AF: Prospective Study With Dabigatran Use -- 2-Year Follow Up (cont)

14. Methodology Matters: Registry Trial Designs

15. Claims-Based Data: Strengths and Weaknesses

16. Dabigatran Use in AF in Real-World Practice: Consistency of Findings

17. ORBIT-AF II: Underdosing of NOACs in AF

18. Danish Study: Nationwide Cohort Study Comparing Effectiveness and Safety of Non-VKAs and NOACs in AF -- Bleeding and Mortality

19. Danish Study: Nationwide Cohort Study Comparing Effectiveness and Safety of Non-VKAs and NOACs in AF -- Composite Endpoint

20. Efficacy and Safety of NOACs: Meta-Analysis of RCTs

21. ENGAGE AF: Increased Stroke Risk With Lower Dose

22. 2016 ESC Guidelines: Recommendations for Stroke Prevention in Patients With AF

23. 2016 ESC Guidelines for AF: Additional Recommendations

24. Loire Valley AF Project: Negative Impact of Aspirin

25. 2014 AHA/ACC/HRS Guidelines for Treatment of AF

26. ORBIT-AF II: Concomitant Aspirin Use

27. 2016 ESC Guidelines for AF: Initiation or Resumption of Anticoagulation in AF Patients After an Intracranial Bleed

28. NOAC Use for AF in the Asian Population

29. How Do We Address Underdosing?

30. Summary

31. Abbreviations

32. Abbreviations (cont)

33. Abbreviations (cont)